Literature DB >> 5576488

Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms.

J R Gibbs, A G Corkill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5576488      PMCID： PMC2467076          DOI： 10.1136/pgmj.47.546.199

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  6 in total

1.  Comparative studies of fibrinolytic inhibitors in vitro.

Authors:  M Maki; F K Beller
Journal:  Thromb Diath Haemorrh       Date:  1966-12-01

2.  Antifibrinolytic therapy for intracranial aneurysms.

Authors:  S Mullan; J Dawley
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

3.  Biochemical changes after spontaneous subarachnoid haemorrhage. 3. Coagulation and lysis with special reference to recurrent haemorrhage.

Authors:  A H Uttley; M Buckell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1968-12       Impact factor: 10.154

4.  Deep hypothermia and surgical treatment of intracranial aneurysms. A five-year survey.

Authors:  A Uihlein; C S MacCarty; J D Michenfelder; H R Terry; E F Daw
Journal:  JAMA       Date:  1966-02-21       Impact factor: 56.272

5.  Fibrinolysis in subarachnoid haemorrhage.

Authors:  J R Gibbs; P O'Gorman
Journal:  Postgrad Med J       Date:  1967-12       Impact factor: 2.401

6.  AMINO METHYL CYCLOHEXANE CARBOXYLIC ACID (AMCHA), A NEW SYNTHETIC FIBRINOLYTIC INHIBITOR.

Authors:  A H DUBBER; G P MCNICOL; A S DOUGLAS
Journal:  Br J Haematol       Date:  1965-03       Impact factor: 6.998
  6 in total
  14 in total

1.  Fibrin-fibrinogen degradation products in cerebrospinal fluid.

Authors:  M J Brueton; G R Breeze; J Stuart
Journal:  J Clin Pathol       Date:  1976-04       Impact factor: 3.411

Review 2.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

3.  Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.

Authors:  S A Tsementzis; E R Hitchcock; C H Meyer
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.

Authors:  S A Tsementzis; W P Honan; S Nightingale; E R Hitchcock; C H Meyer
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 5.  Antifibrinolytic treatment in subarachnoid haemorrhage: present state.

Authors:  H Fodstad
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

6.  Perioperative use of recombinant factor VII to prevent intraoperative aneurysm rupture in high risk patients: a preliminary safety evaluation.

Authors:  Eric S Nussbaum; Tariq M Janjua; Archie Defillo; Penny Sinner; Andrea Zelensky
Journal:  Neurocrit Care       Date:  2008-09-26       Impact factor: 3.210

7.  Tranexamic acid and upper gastrointestinal haemorrhage--a double-blind trial.

Authors:  J C Biggs; T B Hugh; A J Dodds
Journal:  Gut       Date:  1976-09       Impact factor: 23.059

8.  Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study.

Authors:  G Pinna; A Pasqualin; C Vivenza; R Da Pian
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

9.  Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.

Authors:  H Fodstad
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

10.  Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm.

Authors:  A A Ameen; R Illingworth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-03       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.